Oral GLP-1 Breakthrough - Arecor CEO on Improving Bioavailability for Obesity Treatment

Why It Matters

An effective oral GLP‑1 would convert a needle‑dependent therapy into a convenient pill, boosting patient adherence and unlocking a multi‑billion‑dollar market for oral peptide drugs.

Key Takeaways

• Oral GLP‑1 peptides face sub‑1% bioavailability today in patients
• Arecor aims to boost oral GLP‑1 absorption for obesity
• Success could enable pill‑form delivery over injections for patients
• Platform may extend to >100 peptide therapeutics in pipeline
• Improved bioavailability promises sizable commercial upside for Arecor

Summary

The video centers on Arecor’s effort to develop an oral GLP‑1 formulation that overcomes the chronic low‑bioavailability problem plaguing peptide therapeutics, especially for obesity treatment. The CEO highlights that while more than a hundred peptide candidates are in development for cardiometabolic diseases, only two peptide drugs have reached the market, both hampered by sub‑1% oral absorption, forcing patients to rely on injections.

Arecor’s strategy is to engineer a delivery platform that raises oral GLP‑1 bioavailability well above the <1% benchmark set by the existing oral product (Rybelsus/Rebelse). Demonstrating a meaningful increase would not only improve dosing efficiency for obesity but also serve as a proof‑of‑concept for the broader class of peptides, potentially unlocking a pipeline of oral therapies.

The CEO emphasized, “If we can demonstrate this across an oral GLP‑1, then this would be highly translatable to other peptides,” underscoring the commercial upside. He cited patient preference for pills over daily or weekly injections as a key driver for market adoption.

Should Arecor succeed, the shift to an effective oral GLP‑1 could dramatically improve adherence, expand the addressable market for obesity drugs, and create a platform that accelerates the commercialization of dozens of other peptide candidates, reshaping the cardiometabolic therapeutic landscape.

Original Description

Arecor Therapeutics PLC is targeting a pivotal 2026. CEO Sarah Howell outlines plans to launch a Phase 2 trial for next-generation insulin AT278 in partnership with Sequel Med Tech, while advancing an oral GLP-1 program aimed at improving bioavailability beyond current market standards.

With cash runway into 2027 and key clinical milestones ahead, Arecor is positioning for a milestone-driven year.

#ArecorTherapeutics #SarahHowell #AT278 #DiabetesTreatment #InsulinInnovation #OralGLP1 #GLP1 #PeptideTherapeutics #BiotechNews #ClinicalTrials #Phase2Trial #MedTech #Cardiometabolic #HealthcareInnovation #ProactiveInvestors